Join us for a live clinical and regulatory update on the evolving FDA landscape surrounding peptide therapies.

In this session, we’ll break down the most recent FDA developments, including key changes to Category 2 substances and what they mean for your practice. Notably, several legacy peptides previously under scrutiny are now being reconsidered—creating new opportunities for safe, compliant integration into patient care.

What we’ll cover:
✔ Overview of the latest FDA guidance and PCAC activity
✔ What “removed from Category 2” actually means in practice
✔ The return of select legacy peptides and clinical considerations
✔ Risk-mitigated prescribing, documentation, and compliance strategies
✔ Upcoming formulary updates and access through trusted pharmacies

This webinar is designed for providers who want to stay ahead of regulatory changes while continuing to deliver innovative, patient-centered care.